Back to Search
Start Over
The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome.
- Source :
-
Malaria journal [Malar J] 2017 Sep 21; Vol. 16 (1), pp. 383. Date of Electronic Publication: 2017 Sep 21. - Publication Year :
- 2017
-
Abstract
- Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.
- Subjects :
- ATP Binding Cassette Transporter, Subfamily B genetics
ATP Binding Cassette Transporter, Subfamily B metabolism
Angola
Antimalarials pharmacokinetics
Artemether, Lumefantrine Drug Combination
Artemisinins pharmacokinetics
Cytochrome P-450 CYP3A genetics
Cytochrome P-450 CYP3A metabolism
Drug Combinations
Ethanolamines pharmacokinetics
Fluorenes pharmacokinetics
Humans
Prevalence
Recurrence
Treatment Outcome
Antimalarials pharmacology
Artemisinins pharmacology
Ethanolamines pharmacology
Fluorenes pharmacology
Genotype
Malaria drug therapy
Polymorphism, Single Nucleotide
Subjects
Details
- Language :
- English
- ISSN :
- 1475-2875
- Volume :
- 16
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Malaria journal
- Publication Type :
- Academic Journal
- Accession number :
- 28934955
- Full Text :
- https://doi.org/10.1186/s12936-017-2006-6